Physician profile
Sumit Kunwar
NPI 1124332481
$7,092.72
in general payments reported to CMS, 2019-2025
31 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $360 · 2021: $880 · 2022: $452 · 2023: $727 · 2024: $1,204 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $990.69 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Ucb, INC. | $940.10 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $916.48 | 2019-2025 | |
| Pfizer INC. | $840.87 | 2019-2025 | |
| Janssen Biotech, INC. | $579.04 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $578.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $326.53 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $212.16 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $211.91 | 2019-2025 | Taltz, Zepbound |
| Horizon Therapeutics Plc | $199.85 | 2019-2023 | Krystexxa |
| Sobi, INC | $166.54 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $121.68 | 2023-2025 | Strensiq |
| Celgene Corporation | $114.93 | 2019 | |
| Sandoz INC. | $101.74 | 2023-2025 | Hyrimoz, Jubbonti |
| Glaxosmithkline, LLC. | $94.90 | 2019-2025 | Benlysta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $86.77 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $80.26 | 2019-2025 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.55 | 2019-2023 | Cyltezo |
| Invivyd INC | $76.92 | 2024-2025 | Pemgarda |
| Genzyme Corporation | $76.30 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $75.55 | 2023-2025 | Acthar |
| Hikma Pharmaceuticals USA | $47.24 | 2019-2021 | |
| Tersera Therapeutics LLC | $28.99 | 2024 | Quzyttir |
| Boston Scientific Corporation | $27.78 | 2019 | |
| Pacira Therapeutics, INC. | $25.62 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.87 | 2019 | |
| Bioventus LLC | $16.95 | 2020 | |
| Mylan Institutional INC. | $15.45 | 2023 | Hulio |
| Organon LLC | $14.82 | 2024 | |
| Ani Pharmaceuticals, INC. | $14.71 | 2025 | Purified Cortrophin Gel |
| Medexus Pharma, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Kunwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.